The information in this section is not country-specific and may contain information that is outside the approved indications in the country in which you are located.
This site contains information and education for healthcare professionals.
- Explore the importance of TRK fusion proteins as a therapeutic target and understand the clinical use of TRK inhibitors.
- Explain the mechanisms behind TRK fusion-driven tumour biology.
- Provide an overview of the different techniques used for NTRK gene fusion testing.
- Provide recommendations on testing for TRK fusion proteins.
The learning outcomes following completion of these modules include:
- Knowing how and why TRK fusion proteins are a therapeutic target for patients across multiple tumour types.
- Understand the advantages of genomic profiling for NTRK gene fusions and which patients to test.
- Ability to interpret genomic profiling results and select the patients most likely to benefit from TRK inhibitor therapy.
- Knowledge of the clinical data for TRK inhibitors that informs treatment decision making.
- Knowledge and understanding of the different methodologies used for NTRK gene fusion testing.
Information included in this website is compiled from review of the medical literature and expert guidance from:
- Prof Ezra Cohen (medical oncologist at the Moores Cancer Center, San Diego, USA)
- Prof. Fernando Lopez-Rios (molecular and surgical pathologist at Hospital Universitario 12 de Octubre, Madrid, Spain)
- Dr. Jaclyn Hechtman (molecular and surgical pathologist at Memorial Sloan Kettering Cancer Center, New York, USA)
- Prof. Frederique Penault-Llorca (molecular and surgical pathologist at the Comprehensive Regional Cancer Institute Centre Jean PERRIN, Clermont-Ferrand, France)
- Assoc. Prof. Gerald Prager (medical oncologist at the Medical University of Vienna, Austria)
- Prof. Christian Rolfo (medical oncologist at The Tisch Cancer Institute at Mount Sinai Health System, New York, USA)
- Prof. Andrea Sartore-Bianchi (medical oncologist at Ospedale Niguarda and University of Milano, Italy)
- Dr. Silvia Stacchiotti (medical oncologists at Oncologia Medica 2 at Fondazione IRCCS Istituto Nazionale Tumori, Milano, Italy)
Other general information
The section was created in 2019 and updated in 2022 (cut-off date for publications included is June 2022) to provide information on key related topics, including:
- How and why TRK fusion proteins are a potential therapeutic target for selected patients across multiple tumour types.
- Which patients may benefit from TRK inhibitor therapy and, therefore, which patients to test?
- The different tests available and under development that can be used to identify NTRK gene fusions and to select patients who are candidates for TRK inhibitor treatment.
- Which patients to treat with TRK inhibitors based on genomic profiling results.
- How to select the right treatment for the right patient using treatment options based on genomic profiling results and available clinical data